Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Erdafitinibin (JNJ-42756493) teho- ja turvallisuustutkimus potilailla, joilla on virtsaputken syöpä

torstai 24. syyskuuta 2026 päivittänyt: Janssen Research & Development, LLC

Vaihe 2, kaksihaarainen monikeskustutkimus, jossa määritettiin Pan-FGFR-tyrosiinikinaasi-inhibiittorin JNJ-42756493 kahden erilaisen annostusohjelman tehokkuus ja turvallisuus potilailla, joilla on metastaattinen tai kirurgisesti leikkaamaton sukusolusyöpä ja FGFR-syöpä

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

Tutkimuksen yleiskatsaus

Tila

Aktiivinen, ei rekrytointi

Yksityiskohtainen kuvaus

This is a multicenter, open-label study (participants will know the identity of study drugs administered) to evaluate the efficacy and safety of erdafitinib in participants with urothelial cancer. The study comprises a 30-days Screening Phase, a Treatment Phase comprised of 28-day treatment cycles that will continue until disease progression or unacceptable toxicity occurs in a long-term extension (LTE) phase, and a post-treatment Follow-up Phase that will extend from the End-of-Treatment Visit until the participant has died, withdraws consent, is lost to follow-up, or the end of the study, whichever comes first. The end of study is defined as the date when all participants have completed the study treatment (Regimens 1 to 3) and all participants enrolled under the drug-drug interaction (DDI) substudy are no longer receiving treatment with erdafitinib. The purpose of DDI sub-study is to evaluate the interaction of repeated doses of erdafitinib with a sensitive cytochrome 450 (CYP) 3A substrate (midazolam) and with an organic cation transporter 2 (OCT2) probe substrate (metformin). Safety will be monitored throughout the study.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

239

Vaihe

  • Vaihe 2

Laajennettu käyttöoikeus

Hyväksytty myytävänä yleisölle. Katso laajennettu käyttöoikeustietue.

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Aalst, Belgia
      • Brussels, Belgia
      • Charleroi, Belgia
      • Ghent, Belgia
      • Wilrijk, Belgia
      • Badalona, Espanja
      • Barcelona, Espanja
      • Madrid, Espanja
      • Málaga, Espanja
      • Pamplona, Espanja
      • Sabadell, Espanja
      • Santander, Espanja
      • Santiago de Compostela, Espanja
      • Seville, Espanja
      • Valencia, Espanja
      • Daejeon, Etelä -Korea
      • Goyang-si, Etelä -Korea
      • Incheon, Etelä -Korea
      • Seoul, Etelä -Korea
      • Bangalore, Intia
      • Kolkata, Intia
      • Mira Road (East), Intia
      • Nadiād, Intia
      • Beer Yaakov, Israel
      • Beersheba, Israel
      • Haifa, Israel
      • Kfar Saba, Israel
      • Petah Tikva, Israel
      • Tel Aviv, Israel
      • Graz, Itävalta
      • Linz, Itävalta
      • Vienna, Itävalta
      • Chisinau, Moltova
      • Angers, Ranska
      • Bordeaux, Ranska
      • Caen Cédex 05, Ranska
      • Dijon, Ranska
      • Lyon, Ranska
      • Nice, Ranska
      • Nîmes, Ranska
      • Paris, Ranska
      • Saint-Herblain, Ranska
      • Suresnes, Ranska
      • Villejuif, Ranska
      • Bucharest, Romania
      • Cluj-Napoca, Romania
      • Craiova, Romania
      • Iași, Romania
      • Berlin, Saksa
      • Erlangen, Saksa
      • Essen, Saksa
      • Freiburg im Breisgau, Saksa
      • Greifswald, Saksa
      • Göttingen, Saksa
      • Hamburg, Saksa
      • Hanover, Saksa
      • Heidelberg, Saksa
      • München, Saksa
      • Münster, Saksa
      • Regensburg, Saksa
      • Straubing, Saksa
      • Weiden/Opf, Saksa
      • Taichung, Taiwan
      • Tainan, Taiwan
      • Taipei, Taiwan
      • Taoyuan, Taiwan
      • Istanbul, Turkki (Türkiye)
      • Barnaul, Venäjä
      • Moscow, Venäjä
      • Omsk, Venäjä
      • Pyatigorsk, Venäjä
      • Saint Petersburg, Venäjä
      • Ufa, Venäjä
      • Blackburn, Yhdistynyt kuningaskunta
      • Dundee, Yhdistynyt kuningaskunta
      • Essex, Yhdistynyt kuningaskunta
      • London, Yhdistynyt kuningaskunta
      • Metropolitan Borough of Wirral, Yhdistynyt kuningaskunta
      • Plymouth, Yhdistynyt kuningaskunta
      • Sutton, Yhdistynyt kuningaskunta
    • Arizona
      • Sedona, Arizona, Yhdysvallat
    • California
      • Los Angeles, California, Yhdysvallat
      • Orange, California, Yhdysvallat
      • Sacramento, California, Yhdysvallat
      • Stanford, California, Yhdysvallat
    • Colorado
      • Aurora, Colorado, Yhdysvallat
    • District of Columbia
      • Washington D.C., District of Columbia, Yhdysvallat
    • Illinois
      • Chicago, Illinois, Yhdysvallat
    • Iowa
      • Iowa City, Iowa, Yhdysvallat
    • Kentucky
      • Louisville, Kentucky, Yhdysvallat
    • Minnesota
      • Minneapolis, Minnesota, Yhdysvallat
    • Nebraska
      • Omaha, Nebraska, Yhdysvallat
    • Nevada
      • Las Vegas, Nevada, Yhdysvallat
    • New York
      • New York, New York, Yhdysvallat
    • North Carolina
      • Charlotte, North Carolina, Yhdysvallat
    • Oregon
      • Medford, Oregon, Yhdysvallat
      • Tualatin, Oregon, Yhdysvallat
    • Pennsylvania
      • Hershey, Pennsylvania, Yhdysvallat
      • Pittsburgh, Pennsylvania, Yhdysvallat
    • South Carolina
      • Myrtle Beach, South Carolina, Yhdysvallat
    • Tennessee
      • Nashville, Tennessee, Yhdysvallat
    • Texas
      • Dallas, Texas, Yhdysvallat
      • Denton, Texas, Yhdysvallat
      • Houston, Texas, Yhdysvallat
    • Virginia
      • Hampton, Virginia, Yhdysvallat

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Must have histologic demonstration of metastatic or surgically unresectable urothelial cancer. Minor components of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
  • Must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status score 0, 1, or 2
  • Must have adequate bone marrow, liver, and renal function as described in protocol
  • Negative pregnancy test (urine or serum beta human chorionic gonadotropin [b-hCG]) at Screening for women of child bearing potential who are sexually active
  • Must have shown disease progression according to RECIST, version 1.1, following prior chemotherapy for metastatic or surgically unresectable urothelial cancer. Participants who received neoadjuvant or adjuvant chemotherapy and showed disease recurrence or progression according to RECIST, version 1.1, within 12 months of the last dose are considered to have received chemotherapy in the metastatic setting. These participants will be referred to as chemo-refractory participants. (Participants who have shown disease progression according to RECIST, version 1.1 following prior treatment with anti-Programmed death-ligand 1 (anti PDL1/PD1) antibodies are also eligible) For DDI substudy
  • Disease progression following prior chemotherapy for metastatic or surgically unresectable urothelial cancer. Participants who received neoadjuvant or adjuvant chemotherapy and showed disease recurrence or progression within 12 months of the last dose are considered to have received chemotherapy in the metastatic setting

Exclusion Criteria:

  • Received chemotherapy, targeted therapies, definitive radiotherapy, or treatment with an investigational anticancer agent within 2 weeks (in the case of nitrosoureas and mitomycin C, within 6 weeks; in the case of immunotherapy, within 4 weeks) before the first administration of study drug. Localized palliative radiation therapy (but should not include radiation to target lesions) and ongoing bisphosphonates and denosumab, are permitted
  • Has persistent phosphate level greater than upper limit of normal (ULN) during screening (within 14 days of treatment and prior to Cycle 1 Day 1) and despite medical management
  • Has a history of or current uncontrolled cardiovascular disease
  • Females who are pregnant, breast-feeding, or planning to become pregnant within 3 months after the last dose of study drug and males ho plan to father a child while enrolled in this study or within 5 months after the last dose of study drug
  • Has not recovered from reversible toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, or Grade 1 neuropathy)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Erdafitinib (8 milligram)

Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase.

8 mg orally once daily for 28 days on a 28 day cycle.

Muut nimet:
  • JNJ-42756493

Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.

Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Main Study: Percentage of Participants With Best (Overall) Objective Response
Aikaikkuna: From Cycle 1 Day 1 up to 6 years 2 months

Percentage of participants with best (overall) objective response were reported. Best objective response is defined as the best (overall) objective response a participants achieved during the study in the order of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), where CR and PR were confirmed as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. As per RECIST version 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Responders are participants with BOR of CR or PR.

From Cycle 1 Day 1 up to 6 years 2 months
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose

Cmax is the maximum observed plasma concentration of midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

Cmax is the maximum observed plasma concentration of 1-OH-Midazolam (midazolam metabolite) alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Metformin Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)

Cmax is the maximum observed plasma concentration of metformin alone or in combination with erdafitinib

Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Midazolam Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

Tmax is the time to reach the maximum observed plasma concentration of midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

Tmax is the time to reach the maximum observed plasma concentration of 1-OH-Midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)

Tmax is the time to reach maximum observed plasma concentration of metformin alone or in combination with erdafitinib

Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Midazolam Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

AUC(0-last) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration of midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

AUC(0-last) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration of 1-OH-Midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Metformin Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)

AUC(0-last) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration of metformin alone or in combination with erdafitinib.

Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)

AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of 1-OH-Midazolam alone or in combination with erdafitinib.

Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Metformin Alone or in Combination With Erdafitinib
Aikaikkuna: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)

AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of metformin alone or in combination with erdafitinib

Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Main Study: Progression-free Survival (PFS)
Aikaikkuna: From screening up to 6 years 2 months

Progression-free survival is defined as the duration from the date of the first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first, regardless of the use of subsequent anticancer therapy. As per RECIST version 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

From screening up to 6 years 2 months
Main Study: Duration of Response (DoR)
Aikaikkuna: From screening up to 6 years 2 months

DOR is defined as the time (in months) from the date of first observation of response (PR or CR) to the date of the first observation of progression or date of death, whatever the cause based on the RECIST version 1.1. CR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have a reduction in their short axis <10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

From screening up to 6 years 2 months
Main Study: Overall Survival
Aikaikkuna: From screening up to 6 years 2 months

Overall survival is defined as the time from the date of first dose of study drug to the date of the participant's death from any cause.

From screening up to 6 years 2 months
Main Study: Percentage of Participants With Treatment-emergent Adverse Event (TEAEs)
Aikaikkuna: From Day 1 up to 6 years 2 months

Percentage of participants with TEAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are those events that occurred from first dose date through 30 days after last dose date, or day before subsequent anticancer therapy, whichever occurs first.

From Day 1 up to 6 years 2 months
Main Study: Plasma Concentration of Erdafitinib at 2 Hours (C2h)
Aikaikkuna: Cycle 1 Days 1 and 21: Pre-dose up to 2 hours post-dose (each cycle length=28 days)

C2h is the plasma concentration of erdafitinib at 2 hours.

Cycle 1 Days 1 and 21: Pre-dose up to 2 hours post-dose (each cycle length=28 days)
Main Study: Plasma Concentration of Erdafitinib at 4 Hours (C4h)
Aikaikkuna: Cycle 1 Days 1 and 21: Pre-dose up to 4 hours post-dose (each cycle length=28 days)

C4h is the plasma concentration of erdafitinib at 4 hours.

Cycle 1 Days 1 and 21: Pre-dose up to 4 hours post-dose (each cycle length=28 days)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 22. huhtikuuta 2015

Ensisijainen valmistuminen (Todellinen)

Torstai 15. syyskuuta 2022

Opintojen valmistuminen (Arvioitu)

Keskiviikko 31. maaliskuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 29. tammikuuta 2015

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 18. helmikuuta 2015

Ensimmäinen Lähetetty (Arvioitu)

Torstai 19. helmikuuta 2015

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 25. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 24. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • CR105065
  • 2014 (Yhdysvaltain NIH-apuraha/sopimus)
  • 42756493BLC2001 (Muu tunniste: Janssen Research & Development, LLC)
  • 2014-002408-26 (EudraCT-numero)
  • 2023-510273-34-00 (Rekisterin tunniste: EUCT number)
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa